VNDA stock forecast, quote, news & analysis
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients... Show more
Why Vanda Pharmaceuticals (VNDA) Stock Is Down -14% in the Last 30 Days
Key Takeaways
- Vanda Pharmaceuticals (VNDA) declined approximately 14% over the last 30 days, sliding from $6.01 to $5.17, extending a broader quarterly sell-off of roughly 24%.
- The stock has been under sustained pressure following disappointing first-quarter 2026 earnings and revenue that missed analyst consensus estimates in early May.
- An FDA Rare Pediatric Disease Designation for VCA-894A briefly lifted shares in early July, but the gains quickly reversed amid persistent bearish sentiment and a "Sell" rating from Weiss Ratings.
- Despite multiple commercial product launches — including NEREUS for motion sickness and the recent approval of BYSANTI — investor concerns about cash burn and profitability continue to weigh on the stock.
- Analyst ratings remain sharply divided, with H.C. Wainwright maintaining a $21 price target while others flag downside risks, reflecting the high-risk, high-reward profile of the biopharmaceutical name.
Vanda Pharmaceuticals (VNDA) Company Overview and Market Position
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and commercializing innovative therapies for central nervous system disorders and rare diseases. The company's commercial portfolio includes Fanapt (iloperidone) for bipolar I disorder and schizophrenia, HETLIOZ for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis Syndrome, PONVORY for relapsing forms of multiple sclerosis, and NEREUS (tradipitant) for the prevention of motion-induced vomiting. In February 2026, the FDA approved BYSANTI (milsaperidone) for bipolar I disorder and schizophrenia, further expanding Vanda's psychiatric franchise. The company's pipeline includes imsidolimab for generalized pustular psoriasis with a PDUFA date in December 2026, as well as late-stage programs in social anxiety disorder and major depressive disorder. Vanda competes in niche therapeutic categories and attracts investor attention for its diversified CNS-focused portfolio, patent-protected assets, and multiple regulatory catalysts.
Vanda Pharmaceuticals (VNDA) Stock Price Performance: Last 30 Days vs. Quarter
Over the past 30 days, VNDA shares have fallen approximately 14%, declining from a closing price of $6.01 on June 26, 2026, to $5.17 as of July 28. The downtrend accelerated in mid-July, when the stock dropped sharply from $6.58 on July 8 to $5.45 by July 16, and continued sliding through late July. The quarterly performance is even steeper: VNDA traded at $6.84 on April 28, 2026, and has since lost roughly 24% of its value. The bulk of the quarterly damage occurred on May 7, when shares plunged from $7.44 to $6.39 in a single session following the release of first-quarter results that missed both earnings and revenue expectations. The stock has struggled to regain footing ever since, repeatedly failing to hold levels above $6.50.
What Drove VNDA Stock Price in the Last 30 Days
Several converging factors contributed to VNDA's 14% decline over the last 30 days. A brief rally in early July — fueled by the FDA's grant of Rare Pediatric Disease Designation to VCA-894A, Vanda's investigational therapy for Charcot-Marie-Tooth disease type 2S — pushed shares to $6.58 on July 8. However, the momentum evaporated quickly. On July 17, Weiss Ratings reiterated a "Sell (D-)" rating on VNDA, reinforcing bearish sentiment. Broader market caution toward small-cap biopharmaceutical stocks likely added to the selling pressure. Meanwhile, the company's announcements — including participation in the B. Riley Securities Mind, Muscle & Vision Summit on July 16 and the NEREUS IndyCar sponsorship unveiled on July 15 — failed to sustain investor enthusiasm. The lingering impact of the May earnings miss, which showed a net loss of $48.6 million and revenue of $51.7 million below the $55 million consensus, continued to cast a shadow over the stock. Concerns about Vanda's cash burn rate, which stood at roughly $61.5 million in Q1 2026, further dampened risk appetite.
What Drove VNDA Stock Performance Over the Last Quarter
VNDA's quarterly decline of roughly 24% traces back primarily to the first-quarter 2026 earnings report released on May 6. The company posted a loss of $0.82 per share, missing the consensus estimate of a $0.69 loss, while revenue of $51.7 million fell short of the $55 million forecast. The miss triggered a steep 14% single-day drop on May 7. Although Vanda raised its full-year 2026 revenue guidance to $240–$290 million — incorporating expected contributions from newly launched NEREUS — the market focused on ongoing profitability challenges. Fanapt delivered 26% year-over-year growth in Q1, yet HETLIOZ continued to face generic competition headwinds. The quarter also saw important regulatory progress, including FDA acceptance of the imsidolimab Biologics License Application with a December 2026 PDUFA date, and the Rare Pediatric Disease Designation for VCA-894A. Despite these pipeline advancements, the combination of earnings disappointment, elevated operating expenses exceeding $100 million per quarter, and persistent cash consumption dominated the narrative and kept shares under pressure.
Trending AI Robots
For traders seeking to navigate volatile biopharmaceutical stocks like Vanda Pharmaceuticals with a data-driven approach, Tickeron's Trending AI Robots page provides a curated selection of top-performing AI-powered trading bots. Tickeron offers hundreds of AI trading bots actively trading across thousands of tickers, but only the most relevant and consistently high-performing strategies earn a spot in this featured section. These bots vary in trading style, time horizon, and performance metrics — ranging from short-term swing trading algorithms to longer-term trend-following models — giving users the flexibility to align automated strategies with their individual objectives. Exploring the Trending AI Robots section can help investors identify data-driven approaches tailored to current market conditions.
VNDA Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, several catalysts could influence VNDA's trajectory. The most significant near-term event is the FDA decision on imsidolimab for generalized pustular psoriasis, expected by December 12, 2026 — an approval would add a sixth commercial product to Vanda's portfolio and potentially unlock a priority review voucher. The commercial ramp of NEREUS, guided to contribute $10–$30 million in 2026, will be closely scrutinized for early adoption metrics. Additional late-stage clinical readouts are anticipated, including Phase III data for VQW-765 in social anxiety disorder by year-end 2026 and for BYSANTI as an adjunctive treatment for major depressive disorder in early 2027. On the risk side, investors should monitor Vanda's cash position — $202.3 million as of March 31, 2026 — relative to its quarterly burn rate, as well as ongoing generic erosion of HETLIOZ. Macroeconomic factors, including interest rate policy and sector rotation away from small-cap biotech, also remain relevant to the stock's performance. As always, past performance does not guarantee future results, and biopharmaceutical investing carries substantial inherent risk.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
VNDA's RSI Indicator recovers from oversold territory
The RSI Oscillator for VNDA moved out of oversold territory on July 30, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In of the 31 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
VNDA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VNDA as a result. In of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for VNDA turned negative on July 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .
VNDA moved below its 50-day moving average on July 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for VNDA moved below the 200-day moving average on June 26, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VNDA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for VNDA entered a downward trend on June 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. VNDA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.092) is normal, around the industry mean (19.620). P/E Ratio (126.000) is within average values for comparable stocks, (38.277). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.532). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (1.385) is also within normal values, averaging (420.906).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VNDA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of biopharmaceutical products
Industry Biotechnology